Exiqon Expects Initial Data from Blood-Based Colon Cancer Dx in Early 2010
August 27, 2009
Exiqon Expects Initial Data from Blood-Based Colon Cancer Dx in Early 2010
The company also reported its financial results for the first half of 2009, posting a roughly 32 percent rise in revenues and a 28 percent jump in net losses.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Exiqon Presents Data from Colon Cancer Biomarker Study
June 7, 2012 / Gene Silencing News - New Products: Exiqon’s microRNA qPCR Panels
April 25, 2013 / Gene Silencing News - New Products: Exiqon’s microRNA Database Search Tool
April 18, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Exiqon, Alnylam, Life Technologies, and More
February 28, 2013 / Gene Silencing News - New Products: Exiqon's MiRcury RNA Isolation Kit — Biofluids
November 29, 2012 / Gene Silencing News